Overview
The marketing authorisation for Evarrest has been withdrawn at the request of the marketing-authorisation holder.
Evarrest : EPAR - Summary for the public
English (EN) (514.84 KB - PDF)
български (BG) (597.14 KB - PDF)
español (ES) (515.07 KB - PDF)
čeština (CS) (578.52 KB - PDF)
dansk (DA) (518.89 KB - PDF)
Deutsch (DE) (516.28 KB - PDF)
eesti keel (ET) (518.26 KB - PDF)
ελληνικά (EL) (600.8 KB - PDF)
français (FR) (518 KB - PDF)
hrvatski (HR) (535.13 KB - PDF)
italiano (IT) (514.66 KB - PDF)
latviešu valoda (LV) (593.61 KB - PDF)
lietuvių kalba (LT) (538.4 KB - PDF)
magyar (HU) (571.9 KB - PDF)
Malti (MT) (577.35 KB - PDF)
Nederlands (NL) (514.67 KB - PDF)
polski (PL) (576.8 KB - PDF)
português (PT) (536.9 KB - PDF)
română (RO) (1020.06 KB - PDF)
slovenčina (SK) (100.5 KB - PDF)
slovenščina (SL) (567.85 KB - PDF)
Suomi (FI) (513.9 KB - PDF)
svenska (SV) (514.56 KB - PDF)
Product information
Evarrest : EPAR - Product Information
English (EN) (861.4 KB - PDF)
български (BG) (1.55 MB - PDF)
español (ES) (896.44 KB - PDF)
čeština (CS) (1.51 MB - PDF)
dansk (DA) (813.54 KB - PDF)
Deutsch (DE) (845.01 KB - PDF)
eesti keel (ET) (787.41 KB - PDF)
ελληνικά (EL) (1.55 MB - PDF)
français (FR) (818.58 KB - PDF)
hrvatski (HR) (898.08 KB - PDF)
íslenska (IS) (877.78 KB - PDF)
italiano (IT) (816.34 KB - PDF)
latviešu valoda (LV) (1.31 MB - PDF)
lietuvių kalba (LT) (910.1 KB - PDF)
magyar (HU) (1.15 MB - PDF)
Malti (MT) (1.31 MB - PDF)
Nederlands (NL) (827.81 KB - PDF)
norsk (NO) (860 KB - PDF)
polski (PL) (1.32 MB - PDF)
português (PT) (818.67 KB - PDF)
română (RO) (934.43 KB - PDF)
slovenčina (SK) (1.32 MB - PDF)
slovenščina (SL) (1.25 MB - PDF)
Suomi (FI) (923.42 KB - PDF)
svenska (SV) (864.7 KB - PDF)
Latest procedure affecting product information: II/0027/G
15/11/2017
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Evarrest : EPAR - All Authorised presentations
English (EN) (456.24 KB - PDF)
български (BG) (496.48 KB - PDF)
español (ES) (460.12 KB - PDF)
čeština (CS) (486.03 KB - PDF)
dansk (DA) (460.06 KB - PDF)
Deutsch (DE) (459.93 KB - PDF)
eesti keel (ET) (459.94 KB - PDF)
ελληνικά (EL) (496.65 KB - PDF)
français (FR) (459.86 KB - PDF)
hrvatski (HR) (472.28 KB - PDF)
íslenska (IS) (460 KB - PDF)
italiano (IT) (459.91 KB - PDF)
latviešu valoda (LV) (489.48 KB - PDF)
lietuvių kalba (LT) (474.86 KB - PDF)
magyar (HU) (484.42 KB - PDF)
Malti (MT) (490.05 KB - PDF)
Nederlands (NL) (459.69 KB - PDF)
norsk (NO) (459.61 KB - PDF)
polski (PL) (489.07 KB - PDF)
português (PT) (459.81 KB - PDF)
română (RO) (930.92 KB - PDF)
slovenčina (SK) (29.59 KB - PDF)
slovenščina (SL) (483.95 KB - PDF)
Suomi (FI) (460.2 KB - PDF)
svenska (SV) (459.88 KB - PDF)
Product details
- Name of medicine
- Evarrest
- Active substance
- human fibrinogen
- human thrombin
- International non-proprietary name (INN) or common name
- human fibrinogen
- human thrombin
- Therapeutic area (MeSH)
- Hemostasis
- Anatomical therapeutic chemical (ATC) code
- B02BC30
Pharmacotherapeutic group
Local hemostaticsTherapeutic indication
Supportive treatment in adult surgery where standard surgical techniques are insufficient (see section 5.1):
- for improvement of haemostasis.
Authorisation details
- EMA product number
- EMEA/H/C/002515
- Marketing authorisation holder
- Omrix Biopharmaceuticals N. V.
Leonardo Da Vinci Laan 15
1831 Diegem
Belgium - Marketing authorisation issued
- 25/09/2013
- Revision
- 4
Assessment history
Evarrest : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (551.25 KB - PDF)
Evarrest : EPAR - Public assessment report
English (EN) (2.05 MB - PDF)
CHMP summary of positive opinion for Evarrest
English (EN) (504.42 KB - PDF)
More information on Evarrest
Public statement on Evarrest: Withdrawal of the marketing authorisation in the European Union
English (EN) (59.2 KB - PDF)